The specific aims of this program are to evaluate present techniques for flow cytometry of urologic specimens, which are already comparable to conventional cytology, and to encourage further improvements in the technology by research and development through a collaborating network of the major laboratories working in this field. It is expected that this will facilitate transfer of flow cytometry technology from the research to the clinical laboratory, thereby increasing clinical access nationwide to cytologic diagnosis, providing standardized diagnostic criteria and objective rather than (the current) subjective evaluations of cytologic samples. By encouraging the collaboration of cell biologists and engineers with pathologists (cytologists) and urologists, it is expected that new diagnostic features will be devised based on cell biology rather than empirical morphologic criteria, and that this will permit still earlier recognition of cancer (precancer cells), more precise classification and more complete prognostic information for the clinical management of patients with proven or suspected bladder tumors. Less trained laboratory personnel will be able to supplement or replace the highly skilled and highly paid cytotechnologists who perform screening examinations for detection of early carcinoma and precancerous lesions (carcinoma in situ). As a result, it will be possible to screen high risk populations at lower cost, and to lessen the cost of monitoring conservative treatment of bladder tumors by using automated flow cytometry examinations with less frequent hospitalizations for cystoscopy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA041021-03
Application #
3548763
Study Section
(SRC)
Project Start
1985-09-30
Project End
1989-09-30
Budget Start
1987-09-01
Budget End
1989-09-30
Support Year
3
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Memorial Hospital for Cancer & Allied Di
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021
Wheeless, L L; Coon, J S; Cox, C et al. (1991) Precision of DNA flow cytometry in inter-institutional analyses. Cytometry 12:405-12
Bretton, P R; Darzynkiewicz, Z; Henry, E et al. (1990) DNA in situ sensitivity to denaturation in bladder cancer and its correlation with tumor stage. Cancer Res 50:7912-4
Cordon-Cardo, C; Reuter, V E; Finstad, C L et al. (1989) Blood group-related antigens in human kidney: modulation of Lewis determinants in renal cell carcinoma. Cancer Res 49:212-8
Coon, J S; Deitch, A D; de Vere White, R W et al. (1989) Check samples for laboratory self-assessment in DNA flow cytometry. The National Cancer Institute's Flow Cytometry Network experience. Cancer 63:1592-9
Bretton, P R; Herr, H W; Kimmel, M et al. (1989) Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerin. J Urol 141:1332-6
Bretton, P R; Herr, H W; Whitmore Jr, W F et al. (1989) Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol 141:853-6
Wheeless, L L; Coon, J S; Cox, C et al. (1989) Measurement variability in DNA flow cytometry of replicate samples. Cytometry 10:731-8
Bretton, P R; Myc, A; Cordon-Cardo, C et al. (1989) Initial evaluation of a new epithelial antigen (T16) for bivariate flow cytometry of bladder irrigation specimens. Cytometry 10:339-44
Hermansen, D K; Melamed, M R; Coon, J S et al. (1989) Ethanol fixation of bladder irrigation specimens for flow cytometric analysis. A multiinstitutional study from the bladder cancer flow cytometry network. Cancer 63:1780-3
Coon, J S; Deitch, A D; de Vere White, R W et al. (1988) Interinstitutional variability in DNA flow cytometric analysis of tumors. The National Cancer Institute's Flow Cytometry Network Experience. Cancer 61:126-30

Showing the most recent 10 out of 19 publications